Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

David Penson

Vanderbilt University Medical Center

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

40%

Health Economics

40%

Prostate Cancer

70%

Oncology

40%

Cancer Therapy

30%

Healthcare Utilization

20%

Pharmacoepidemiology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare

Article Link

Year:

2023

Point-Counterpoint: Clinical Pragmatism Should Prevail Over Biological Orthodoxy: “Pro” Perspective

Article Link

Year:

2023

Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer

Article Link

Year:

2023

Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer

Article Link

Year:

2023

Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer

Article Link

Year:

2022

Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer

Article Link

Year:

2022

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

Article Link

Year:

2022

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

Article Link

Year:

2022

Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region

Article Link

Year:

2021

Out-of-pocket costs for commercially insured patients with localized prostate cancer

Article Link

Year:

2021

Collaborators3

Daniel Barocas

Professor and Executive Vice Chair

Vanderbilt University Medical Center

UNITED STATES

Christopher J.D. Wallis

CANADA

Bashir Al Hussein Al Awamlh

Cornell University

UNITED STATES

How do I reach out?

Meet Kite AI